科研动态PubMed 摘要

莫塞妥珠瑞泽替康治疗卵巢癌和子宫内膜癌的BEHOLD 3期临床开发项目。

PubMed 白名单日捞 · 2026-11-11

完整摘要 · 中文译文

Mocertatug rezetecan(Mo-Rez;GSK5733584)是一种靶向B7-H4的抗体偶联药物,由人源化抗B7-H4单克隆抗体与拓扑异构酶I抑制剂rezetecan连接而成。在1期BEHOLD-1研究(NCT06431594)中,Mo-Rez在铂耐药卵巢癌(客观缓解率[ORR],62%)和复发/晚期子宫内膜癌(ORR,67%)中显示出令人鼓舞的抗肿瘤活性,支持在3期研究中进一步开展临床评估。全球BEHOLD 3期临床项目包括五项随机研究,评估Mo-Rez在卵巢癌和子宫内膜癌不同治疗场景中的应用,计划入组约3,070例患者。卵巢癌研究评估铂耐药疾病(BEHOLD-Ovarian01,NCT07286266)、铂敏感疾病(BEHOLD-Ovarian02,NCT076684612)以及非同源重组缺陷疾病的一线维持治疗(BEHOLD-Ovarian03,NCT07694427)。子宫内膜癌研究评估既往接受过治疗的晚期/复发性疾病(BEHOLD-Endometrial01,NCT07286331)以及错配修复功能完整疾病的一线维持治疗(BEHOLD-Endometrial02,NCT07684599)。主要终点包括无进展生存期(PFS)和总生存期(OS),具体取决于研究设计。次要和探索性终点包括安全性、药代动力学、生物标志物、免疫原性和生活质量评估。总体而言,BEHOLD项目评估三种治疗策略:以B7-H4导向的ADC替代传统化疗、与贝伐珠 umab或免疫检查点抑制剂,以及使用Mo-Rez作为维持治疗。跨研究收集肿瘤组织能够前瞻性评估B7-H4表达及其他生物标志物作为临床获益预测因素的作用。BEHOLD项目是一项全面的3期临床开发工作,旨在评估Mo-Rez在多种卵巢癌和子宫内膜癌情境中的疗效和安全性,并进一步明确B7-H4作为妇科恶性肿瘤治疗靶点的临床相关性。

完整摘要 · 英文原文

Mocertatug rezetecan (Mo-Rez; GSK5733584) is a B7-H4-targeting antibody-drug conjugate comprising a humanized anti-B7-H4 monoclonal antibody linked to the topoisomerase I inhibitor rezetecan. In the Phase 1 BEHOLD-1 study (NCT06431594), Mo-Rez demonstrated encouraging antitumor activity in platinum-resistant ovarian cancer (objective response rate [ORR], 62%) and recurrent/advanced endometrial cancer (ORR, 67%), supporting further clinical evaluation in Phase 3 studies. The global BEHOLD Phase 3 clinical program consists of five randomized studies evaluating Mo-Rez across ovarian and endometrial cancer treatment settings, with approximately 3,070 patients planned for enrollment. The ovarian cancer studies evaluate platinum-resistant disease (BEHOLD-Ovarian01, NCT07286266), platinum-sensitive disease (BEHOLD-Ovarian02, NCT076684612), and first-line maintenance for non-homologous recombination deficient disease (BEHOLD-Ovarian03, NCT07694427). The endometrial cancer studies evaluate previously treated advanced/recurrent disease (BEHOLD-Endometrial01, NCT07286331) and first-line maintenance for mismatch repair proficient disease (BEHOLD-Endometrial02, NCT07684599). Primary endpoints include progression-free survival (PFS) and overall survival (OS), depending on study design. Secondary and exploratory endpoints include safety, pharmacokinetics, biomarkers, immunogenicity, and quality-of-life assessments. Collectively, the BEHOLD program evaluates three therapeutic strategies: replacement of conventional chemotherapy with a B7-H4-directed ADC, combination approaches with bevacizumab or immune checkpoint inhibitors, and use of Mo-Rez as maintenance therapy. Tumor tissue collection across studies enables prospective evaluation of B7-H4 expression and other biomarkers as predictors of clinical benefit. The BEHOLD program represents a comprehensive Phase 3 clinical development effort designed to evaluate the efficacy and safety of Mo-Rez across multiple ovarian and endometrial cancer settings and to further characterize the clinical relevance of B7-H4 as a therapeutic target in gynecologic malignancies.

English
BEHOLD phase 3 clinical development program of mocertatug rezetecan in ovarian and endometrial cancer.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界